|
WO2020254554A1
|
|
Process for the preparation of clc-1 chloride channel inhibitors
|
|
WO2020254559A1
|
|
Compounds for the treatment of neuromuscular disorders
|
|
WO2020254553A1
|
|
Compounds for the treatment of neuromuscular disorders
|
|
WO2020254558A1
|
|
5-[(1s)-1-(4-bromophenoxy)ethyl]-2h-tetrazole derivatives and related compounds as clc-1 ion channel inhibitors for treating neuromuscular disorders
|
|
EP3753560A1
|
|
Compounds for the treatment of neuromuscular disorders
|
|
US2019183812A1
|
|
Compounds For The Treatment Of Neuromuscular Disorders
|
|
US2019183834A1
|
|
Compounds For The Treatment Of Neuromuscular Disorders
|
|
US2019183863A1
|
|
Compounds For The Treatment Of Neuromuscular Disorders
|
|
TW201927753A
|
|
Compounds for the treatment of neuromuscular disorders
|
|
TW201927738A
|
|
Compounds for the treatment of neuromuscular disorders
|
|
TW201938525A
|
|
Compounds for the treatment of neuromuscular disorders
|
|
AU2016279486A1
|
|
Compounds for use in treating neuromuscular disorders
|
